Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status
Jan‐Malte Placke(Düsseldorf University Hospital), Selma Ugurel(Klinikum Bielefeld), Jochen Utikal(German Cancer Research Center), Rudolf Herbst(Helios Klinikum Erfurt), Klaus Griewank(Düsseldorf University Hospital), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Claudia Pföhler(Saarland University), Alexander Roesch(Essen University Hospital), Luisa Sophie Rajcsanyi(University of Duisburg-Essen), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Frederik Krefting(University of Duisburg-Essen), Alpaslan Tasdogan(Düsseldorf University Hospital), Elisabeth Livingstone(German Cancer Research Center), Lisa Zimmer(The University of Sydney), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Ulrike Leiter(University of Tübingen), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Patrick Terheyden(University Hospital Schleswig-Holstein), Georg Lodde(Essen University Hospital), Carola Berking(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k